NCT00567528

Brief Summary

This study was made to compare the efficacy of topical ibuprofen in gel form with oral ibuprofen in the treatment of sub-acute soft tissue injuries while comparing the tolerability of the delivery methods

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2006

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2006

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

December 3, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 5, 2007

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2009

Completed
Last Updated

January 14, 2015

Status Verified

January 1, 2012

Enrollment Period

2.9 years

First QC Date

December 3, 2007

Last Update Submit

January 13, 2015

Conditions

Keywords

Soft tissue injuriesTopical ibuprofenAdolescent athletes

Outcome Measures

Primary Outcomes (1)

  • Efficacy of Topical Ibuprofen to Oral Ibuprofen measured by numeric pain rating, swelling at injury site, and change in sports activity.

    10 days to 8 weeks after initial injury or flare up

Secondary Outcomes (1)

  • Compare the tolerability of the two delivery methods measured by side effects.

    2 weeks after starting topical and oral ibuprofen

Study Arms (2)

1

OTHER

Active ibuprofen liposomal transdermal gel with placebo ibuprofen capsule

Drug: ibuprofen

2

OTHER

Placebo ibuprofen liposomal transdermal gel with active ibuprofen capsules

Drug: Ibuprofen

Interventions

Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.

2

Eligibility Criteria

Age12 Years - 19 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Age 12-19yo
  • soft tissue injury or flare up of soft tissue injury within 10 days to 8 weeks

You may not qualify if:

  • Known hypersensitivity to aspirin or any NSAID,
  • allergy to eggs or egg products
  • history of asthma, renal disease, GI disease, active or suspected bleeding peptic ulcer (past or present), anemia, hypertension, other systemic disease significantly affecting liver or renal function
  • serious injury within six months
  • currently on anticoagulants
  • pregnant or lactating females
  • active arthritis in affected limb
  • open wounds, infected skin or fractures
  • opioid use within 7 days
  • severe psychological disorder
  • prior topical medication applied to the painful region/area of study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sports Medicine Department at Akron Children's Hospital

Akron, Ohio, 44308, United States

Location

Related Publications (1)

  • Whitefield M, O'Kane CJ, Anderson S. Comparative efficacy of a proprietary topical ibuprofen gel and oral ibuprofen in acute soft tissue injuries: a randomized, double-blind study. J Clin Pharm Ther. 2002 Dec;27(6):409-17. doi: 10.1046/j.1365-2710.2002.00439.x.

    PMID: 12472980BACKGROUND

MeSH Terms

Conditions

Soft Tissue Injuries

Interventions

Ibuprofen

Condition Hierarchy (Ancestors)

Wounds and Injuries

Intervention Hierarchy (Ancestors)

PhenylpropionatesAcids, CarbocyclicCarboxylic AcidsOrganic Chemicals

Study Officials

  • Emmanuel O Adekunle, M.D.

    Akron Children's Hospital

    PRINCIPAL INVESTIGATOR
  • Joseph Congeni, M.D.

    Akron Children's Hospital

    STUDY DIRECTOR
  • Cynthia Bennett, MSN, CNP

    Akron Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
M.D.

Study Record Dates

First Submitted

December 3, 2007

First Posted

December 5, 2007

Study Start

May 1, 2006

Primary Completion

April 1, 2009

Study Completion

April 1, 2009

Last Updated

January 14, 2015

Record last verified: 2012-01

Locations